BioventusBVS
About: Bioventus Inc is a medical technology company. The company is engaged in developing and commercializing clinically differentiated treatments that engage and enhance the body's natural healing process. It offers a diverse portfolio of products to serve physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine and neurosurgery. Its portfolio of products is grouped into three verticals based on clinical use: Pain Treatments, Surgical Solutions, and Restorative Therapies. Geographical presence is in the United States which derives key revenue, and International markets.
Employees: 1,030
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
225% more first-time investments, than exits
New positions opened: 52 | Existing positions closed: 16
110% more capital invested
Capital invested by funds: $256M [Q2] → $537M (+$282M) [Q3]
67% more repeat investments, than reductions
Existing positions increased: 40 | Existing positions reduced: 24
35% more funds holding
Funds holding: 102 [Q2] → 138 (+36) [Q3]
33% more funds holding in top 10
Funds holding in top 10: 3 [Q2] → 4 (+1) [Q3]
0.7% less ownership
Funds ownership: 69.64% [Q2] → 68.94% (-0.7%) [Q3]
11% less call options, than puts
Call options by funds: $2.32M | Put options by funds: $2.6M
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
JP Morgan Robbie Marcus 48% 1-year accuracy 10 / 21 met price target | 22%upside $13 | Neutral Upgraded | 17 Dec 2024 |
Canaccord Genuity William Plovanic 57% 1-year accuracy 26 / 46 met price target | 41%upside $15 | Buy Maintained | 6 Nov 2024 |
Craig-Hallum Alexander Nowak 64% 1-year accuracy 9 / 14 met price target | 59%upside $17 | Buy Maintained | 27 Sept 2024 |
Financial journalist opinion
